Abstract

Background: The lifespan of Marfan Syndrome (MFS) patients is shortened, especially in patients without early diagnostics, preventive treatment, and elective surgery. Clinically, MFS diagnosis is mainly dependent on phenotypes, but for children, sporadic cases, or suspicious MFS patients, molecular genetic testing, and mainly FBN1 mutation screening, plays a significant role in the diagnosis of MFS. PGT-M gives couples that had a family history of monogenic disorders the opportunity to avoid the occurrence of MFS. Methods: In this study, 11 families with MFS were recruited and complete clinical features were collected. Variants were classified and interpreted through pedigree analysis according to guidelines. Two families chose to undergo PGT-M; 16 blastocysts were biopsied and amplified. Haplotype analysis was performed to deduce the embryo’s genotype by using single nucleotide polymorphisms (SNPs) identified in each sample. Results: We identified 11 potential disease-causing FBN1 variants, six of which are novel. All variants were assessed with prediction tools to assess mutation pathogenicity, population databases to evaluate population allele frequency, literature databases to identify whether the variant had been reported in MFS patients, and multiple sequence alignment to carry out conservative analysis. Finally, nine variants were classified as likely pathogenic/pathogenic variants. Among 11 variants, eight variants were missense, and seven of them were located in the Ca-binding EGF-like motifs, moreover, half of them substituted conserved Cysteine residues. We also identified a splice site variant, a frameshift variant, and a synonymous variant. There are two variants that are de novo variants. PGT-M helped two MFS families give birth to a healthy baby not carrying the FBN1 mutation. Conclusions: In the present study, the FBN1 mutation spectrum was enriched, and may help further elucidate the pathogenesis, benefiting clinical diagnosis and management of MFS. We make use of a reliable PGT-M method for the successful birth of healthy babies to two MFS families.

Highlights

  • Marfan syndrome (MFS, OMIM 154700) is a connective tissue disease that is caused by mutations in fibrillin-1; it mainly affects several systems including cardiovascular, ocular, and musculoskeletal systems

  • We found that the clinical phenotypes of Marfan Syndrome (MFS) patients in the same family are broadly similar and remain different

  • In Family 1, two children (12 and 15 years old) did not have cardiac phenotypes such as aortic dilatation, aortic dissection, and mitral valve prolapse but adults had; it reminded us that molecular genetic testing for children or atypical MFS patients is important and to warn patients to take medical prophylaxis to prevent cardiovascular pathologies causing the highest mortality in MFS (Comeglio et al, 2007; Franken et al, 2017; Manchola-Linero et al, 2018)

Read more

Summary

Introduction

Marfan syndrome (MFS, OMIM 154700) is a connective tissue disease that is caused by mutations in fibrillin-1; it mainly affects several systems including cardiovascular, ocular, and musculoskeletal systems. MFS diagnosis is mainly dependent on manifestations or phenotypes (Loeys et al, 2010), but for children or suspicious MFS patients, molecular genetic testing, and mainly FBN1 mutation screening, plays a significant role in the diagnosis of MFS (Cañadas et al, 2010; Groth et al, 2017). There is a specific guideline for the interpretation of sequenced variants in the FBN1 Gene for Marfan Syndrome besides the American College of Medical Genetics (ACMG) guideline to help us identify novel mutations in FBN1 likely to cause MFS (MuiñoMosquera et al, 2018). The lifespan of Marfan Syndrome (MFS) patients is shortened, especially in patients without early diagnostics, preventive treatment, and elective surgery. MFS diagnosis is mainly dependent on phenotypes, but for children, sporadic cases, or suspicious MFS patients, molecular genetic testing, and mainly FBN1 mutation screening, plays a significant role in the diagnosis of MFS.

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call